Circulating bile acid concentrations and non-alcoholic fatty liver disease in Guatemala
- PMID: 35484638
- PMCID: PMC9233027
- DOI: 10.1111/apt.16948
Circulating bile acid concentrations and non-alcoholic fatty liver disease in Guatemala
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a major liver disease worldwide. Bile acid dysregulation may be a key feature in its pathogenesis and progression.
Aims: To characterise the relationship between bile acid levels and NAFLD at the population level METHODS: We conducted a cross-sectional study in Guatemala in 2016 to examine the prevalence of NAFLD. Participants (n = 415) completed questionnaires, donated blood samples and had a brief medical exam. NAFLD was determined by calculation of the fatty liver index. The levels of 15 circulating bile acids were determined by LC-MS/MS. Adjusted prevalence odds ratios (PORadj ) and 95% CI were calculated to examine the relationships between bile acid levels (in tertiles) and NAFLD.
Results: Persons with NAFLD had significantly higher levels of the conjugated primary bile acids glycocholic acid (GCA) (PORadj T3 vs T1 = 1.85), taurocholic acid (TCA) (PORadj T3 vs T1 = 2.45) and taurochenodeoxycholic acid (TCDCA) (PORadj T3 vs T1 = 2.10), as well as significantly higher levels the unconjugated secondary bile acid, deoxycholic acid (DCA) (PORadj T3 vs T1 = 1.78) and its conjugated form, taurodeoxycholic acid (TDCA) (PORadj T3 vs T1 = 1.81).
Conclusions: The bile acid levels of persons with and without NAFLD differed significantly. Among persons with NAFLD, higher levels of the conjugated forms of CA (i.e. GCA, TCA) and the secondary bile acids that derive from CA (i.e. DCA, TDCA) may indicate there is hepatic overproduction of CA, which may affect the liver via aberrant signalling mediated by the bile acids.
© 2022 John Wiley & Sons Ltd.
Conflict of interest statement
Comment in
-
Letter: association of circulating bile acid concentrations and non-alcoholic fatty liver disease-authors' reply.Aliment Pharmacol Ther. 2022 Jul;56(2):374-375. doi: 10.1111/apt.17059. Aliment Pharmacol Ther. 2022. PMID: 35748838 No abstract available.
-
Editorial: higher levels of certain serum bile acids in non-alcoholic fatty liver disease-new insights from Guatemala.Aliment Pharmacol Ther. 2022 Jul;56(2):357-360. doi: 10.1111/apt.16962. Aliment Pharmacol Ther. 2022. PMID: 35748840 No abstract available.
-
Letter: association of circulating bile acid concentrations and non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2022 Jul;56(2):372-373. doi: 10.1111/apt.16986. Aliment Pharmacol Ther. 2022. PMID: 35748845 No abstract available.
-
Editorial: higher levels of certain serum bile acids in non-alcoholic fatty liver disease-new insights from Guatemala.Authors' reply.Aliment Pharmacol Ther. 2022 Jul;56(2):361-362. doi: 10.1111/apt.17061. Aliment Pharmacol Ther. 2022. PMID: 35748846 No abstract available.
-
Letter: is it appropriate to use a fatty liver index >60 as an alternative criterion for non-alcoholic fatty liver disease?Aliment Pharmacol Ther. 2022 Jul;56(2):376-377. doi: 10.1111/apt.17041. Aliment Pharmacol Ther. 2022. PMID: 35748848 No abstract available.
-
Letter: is it appropriate to use a fatty liver index >60 as an alternative criterion for non-alcoholic fatty liver disease? Authors' reply.Aliment Pharmacol Ther. 2022 Jul;56(2):378-379. doi: 10.1111/apt.17060. Aliment Pharmacol Ther. 2022. PMID: 35748850 No abstract available.
References
-
- Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020;72(5):1605–1616. - PubMed
-
- Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–285. - PubMed
-
- Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134–140. - PubMed
-
- Le MH, Yeo YH, Li X, et al. 2019 global NAFLD prevalence - A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021. - PubMed
-
- Arab JP, Diaz LA, Dirchwolf M, et al. NAFLD: Challenges and opportunities to address the public health problem in Latin America. Ann Hepatol. 2021;24:100359. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical